Search Results
Showing Results for clinical
A recent study published in the American Journal of Ophthalmology has revealed significant levels of burnout among uveitis specialists in the United States, with 41% of surveyed physicians reporting symptoms of burnout and nearly 50% considered at risk. The cross-sectional survey, distributed through the American Uveitis Society (AUS) and Young Uveitis Society (YUS), used the validated Mini Z 2.0 tool to assess burnout levels.
Encouraging results have emerged from two phase II clinical trials investigating a novel treatment, PER-001, for glaucoma and diabetic retinopathy, two of the most common causes of blindness globally. Delivered via a sustained-release intravitreal implant every six months, PER-001 improved both vision and retinal structure compared with control groups.
The FDA has approved TRYPTYR® (acoltremon ophthalmic solution) 0.003%, a novel prescription eye drop developed by Alcon, for the treatment of both the signs and symptoms of the condition.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
The European Commission has granted market authorization for Ryjunea®, a low-dose atropine eye drop developed by Santen Pharmaceutical Co., Ltd., For the first time in Europe, children struggling with worsening vision have a clinically proven treatment to slow myopia
We are delighted to share the latest issue of touchREVIEWS in Ophthalmology, showcasing a diverse range of articles that highlight the innovation, interdisciplinary collaboration and continued advances driving progress in eye care today. We begin this issue with an important ...
Taking place from 7–9 June 2025 in Lisbon, Portugal, the SOE Congress is one of Europe's leading multi-specialty ophthalmology meetings. With a world-class scientific programme, this in-person event offers a rich mix of symposia, live surgery, debates, workshops, mystery cases and updates ...
Susvimo® (ranibizumab injection) has become the first FDA-approved continuous delivery system for diabetic retinopathy (DR), reducing treatment frequency to once every nine months.1 The approval is based on the positive results of the phase III Pavilion study, showing significant improvement in disease severity.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Breast carcinoma is the most common cancer in females. An estimated 2.3 million new cases of breast carcinoma are diagnosed annually worldwide.1Â These patients have potential risks of ocular complications not only from the secondaries in the eye but also due ...
In this expert Q&A, we speak with Dr Samir Jabbour, Assistant Clinical Professor at the University of Montreal and Adjunct Clinical Professor at McGill University, who also practices at the Centre hospitalier de l'Université de Montréal (CHUM) and Jewish General Hospital (JGH). Dr Jabbour shares insights from his presentation on the evolving role of combining refractive procedures with corneal crosslinking (CXL) for patients with keratoconus and post-refractive ectasia. He discusses clinical indications, patient selection, benefits and risks of simultaneous versus sequential approaches, and the technologies driving the next wave of personalized corneal treatments.
The World Cornea Congress IX, held from March 20–22, 2025, in Washington, D.C., brought together over 1,200 ophthalmologists to explore the latest in corneal disease and surgery. Held every five years, the event featured symposia, scientific sessions, exhibits, and networking, with a focus on advances in corneal transplantation. In this Q&A, Prof. M Vanathi, Professor of Ophthalmology at the All India Institute of Medical Sciences, New Delhi, shares insights on the role of therapeutic keratoplasty in treating severe corneal infections, surgical planning, and future directions in this vision-saving procedure.
During the WCC IX congress, Prof. Elisabeth Cohen, Department of Ophthalmology at NYU Grossman School of Medicine, delivered a presentation on the Management of Zoster Keratitis. In the following Q&A, she shares her clinical insights on diagnosis, treatment strategies, and prevention of this complex and often under-recognized condition.
The FDA has accepted an NDA for SYD-101, a proprietary low-dose atropine formulation developed to slow paediatric myopia progression. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 23, 2025.
On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
